What is the purpose of the Bortezomib 3.5mg Injection Mibor?
The medication Bortezomib 3.5mg Injection Mibor is used to treat multiple myeloma, a type of cancer of the bone marrow. Bortezomib is also used to treat mantle cell lymphoma, a disease that starts in immune system cells and grows quickly. Bortezomib belongs to the antineoplastic agent class of medicines.
Is bortezomib a type of chemotherapy?
Velcade (bortezomib) is a targeted therapy, which is a kind of chemotherapy. Velcade is a proteasome inhibitor, which is a sort of medicine. The FDA has given it the approval to treat multiple myeloma and mantle cell lymphoma.
What are the bortezomib side effects?
- loss of appetite
- or pain/redness at the injection site are all possible side effects. Nausea, vomiting, and diarrhea are all common side effects.
- Your primary care physician might prescribe drugs to forestall or lighten sickness, heaving, or the runs in certain conditions.
For more details Click Here.
Is bortezomib associated with hair loss?
Hair loss is a common occurrence. Going bald is definitely not an immediate result of Velcade, yet it very well may be brought about by different meds you’re taking with it. Individuals utilizing Velcade in addition to the cytotoxic medicine cyclophosphamide, for instance, may encounter going bald.
Is bortezomib an oral medication?
Dizziness, lightheadedness, nausea, vomiting, loss of appetite, diarrhea, constipation, fatigue, weakness, or pain/redness at the injection site are all possible side effects. The new version of Velcade (bortezomib) may be more effective and well-tolerated than Velcade injections.
How is Bortezomib 3.5mg Injection Mibor administered?
Bortezomib 1 mg powder for solution for injection is given intravenously twice weekly for two weeks at a dose of 1.3 mg/m2 of body surface area on days 1, 4, 8, and 11 of a 21-day treatment cycle. A treatment cycle is defined as a three-week period.
How frequently is Bortezomib 3.5mg Injection Mibor administered?
For two weeks (Days 1, 4, 8, and 11), VELCADE is administered twice weekly, followed by a ten-day respite from Days 12 to 21. Two further VcR-CAP cycles are advised for patients who had a response to Cycle 6. At least 72 hours should pass between successive VELCADE doses.
Bortezomib 3.5mg Injection Mibor is a type of medication.
Bortezomib is a proteasome inhibitor, which is a kind of malignant growth treatment medication. Cells contain proteasomes. They aid in the breakdown of proteins that aren’t needed by the cell.